Brief: Helix Acquisition Corp. II Retains More Than 60% Of Trust Account
06/08/2025 13:10
Aug 6 (Reuters) - BridgeBio Pharma Inc BBIO.O: HELIX ACQUISITION CORP. II RETAINS MORE THAN 60% OF TRUST ACCOUNT AFTER REDEMPTIONS IN CONNECTION WITH BUSINESS COMBINATION WITH BRIDGEBIO ONCOLOGY THERAPEUTICS Source text: ID:nGNX4515PV Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels